You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The single-cell genomics firm's agreements with multiple companies will cover Japan, South Korea, Taiwan, Australia, and New Zealand.
The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO.
he single-cell microbiome sequencing firm has raised a total of ¥1.5 billion in equity financing since its founding in 2018.
Labs are finding cheaper, higher-throughput ways to determine the inflection points in gene expression within a particular cell.
The de novo directional genomic hybridization technology is designed to enable the measurement of simple, complex, and heterogenous structural variants.
The firm's $42.9 million in total revenues and $.41 loss per share for the second quarter both beat the average analyst estimates.
The court also ordered a new trial to determine if 10x's products infringe reconstructed patents held by Bio-Rad Laboratories.
Two companies offering droplet-based single-cell RNA sequencing sample prep, 10x Genomics and 1Cellbio, have launched dual-indexed library preparation products.
Codefendant 1Cellbio, an instrument maker that had obtained a co-exclusive license to the patents, said it plans to appeal the court's declaration.
The company will apply its single-cell RNA-seq analytics technology to three distinct cohorts in pursuit of new drug targets for inflammatory bowel disease.
A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.
According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.
In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.